Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0472-0147 · 1 trial · 2 indications
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0472-0147 Part 1 | EXPERIMENTAL | Part 1: Each cohort will consist of 8 healthy subjects - 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0472-0147. |
| Placebo Part 1 | PLACEBO_COMPARATOR | Part 1: Each cohort will consist of 8 healthy subjects - 2 subjects will receive a single s.c. dose of placebo. |
| NNC0472-0147 Part 2 | EXPERIMENTAL | Part 2: Each cohort will consist of 12 subjects with T2DM. 9 subjects will receive once daily s.c. doses of NNC0472-0147 for 14 days |
| Insulin glargine Part 2 | ACTIVE_COMPARATOR | Part 2: Each cohort will consist of 12 subjects with T2DM - 3 subjects will receive once daily s.c. doses of insulin glargine for 14 days. |
| Name | Type | Description |
|---|---|---|
| NNC0472-0147 | DRUG | Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort. |
| insulin glargine | DRUG | Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts. |
| Placebo (NNC0472-0147) | DRUG | Part 1: A single dose of placebo, dose increased in each cohort. |
Inclusion Criteria: Part 1: * Male * Aged 18-55 years (both inclusive) at the time of signing nformed consent. Part 2: * Male, or female of non-child bearing potential. Non-child bearing potential is defined by being surgically sterilised (documented hysterectomy, bilateral salpingectomy or bila...
NNC0472-0147 is an investigational small molecule being developed by Novo Nordisk for metabolic conditions. It is currently in Phase 1 clinical development, studied in healthy volunteers and people with type 2 diabetes. The drug is not approved and remains in clinical trials.
NNC0472-0147 is developed by Novo Nordisk A/S, a pharmaceutical company traded on the NYSE under the ticker NVO. The company is conducting clinical trials to evaluate the safety of this investigational small molecule in healthy volunteers and individuals with type 2 diabetes.
NNC0472-0147 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It is not approved by regulatory authorities and is still being studied for safety in healthy volunteers and people with type 2 diabetes.
NNC0472-0147 has one completed Phase 1 trial, NCT04262661, titled "A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes." The trial enrolled 36 participants in Germany and was randomized, double-blind, and placebo-controlled.
NNC0472-0147 is not FDA approved. It is an investigational drug in Phase 1 clinical development. A completed Phase 1 trial assessed its safety in healthy volunteers and people with type 2 diabetes, but the drug has not received regulatory approval for any use.